Author:
Touzeau C,Ryan J,Guerriero J,Moreau P,Chonghaile T N,Le Gouill S,Richardson P,Anderson K,Amiot M,Letai A
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference17 articles.
1. Letai AG . Diagnosing and exploiting cancer’s addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121–132.
2. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351–365.
3. BCL-2 inhibitor yields high response in CLL and SLL. Cancer Discov 2014; 4: OF5.
4. Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) Is active and well-tolerated in patients with relapsed Non-Hodgkin lymphoma: interim results of a Phase I study. ASH Annu Meet Abstr 2012; 120: 304.
5. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202–208.
Cited by
122 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献